Skip to main content
. 2014 Nov 18;23(1):108–118. doi: 10.1038/mt.2014.204

Figure 1.

Figure 1

Expression of hyaluronic acid (HA) in established and patient-derived GBM xenografts. (a–d) GBM xenografts were generated by intracranial implantation of different established or patient-derived GBM lines in mice. (a) Evaluation of HA levels in established U87 by histochemical analysis using the biotinylated hyaluronan-binding protein (HABP-b) in untreated (left) and pretreated tumor section with soluble hyaluronidase (right). (b–e) Evaluation of tumor formation (hematoxylin and eosin staining) and HA levels (histochemical staining) from brain sections within (b) different established, (c) nodular patient-derived, (d) and invasive patient-derived GBM xenografts. (e) Plot showing HA staining quantification normalized to the staining measured in hyaluronidase-treated tumor sections. Bar = 50 µm. Mean + SE (n = 3) is plotted. **P < 0.01; *P < 0.05 versus Gli36vIII HA-negative tumor model (t-test, two-sided).